Application of isaria felina mycelium powder in preparation of liver protection medicine
By using cat rod sporal hyphae powder as a drug ingredient for liver protection, the problem of lack of safe and effective natural drug intervention in the treatment of NAFLD in the prior art has been solved, which significantly improves dyslipidemia and liver damage of NAFLD, and prevents the aggravation of the disease.
Patent Information
- Application Number
- CN202410984421.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-22
- Publication Date
- 2024-11-12
AI Technical Summary
The prior art has not yet developed a safe and effective and hepatotoxic natural drug intervention for the treatment of non-alcoholic fatty liver disease (NAFLD), especially in preventing its worsening toward a more severe form.
Isaria felina mycelium powder (IFMP) is used as the ingredient of liver protection drugs, and a powder is prepared through specific fermentation and culture methods to improve NAFLD-related dyslipidemia and liver damage.
By regulating blood lipids and liver function levels, reducing liver lipid deposition and enhancing antioxidant effects, significantly improving pathological changes in NAFLD and reducing the risk of liver damage.
Smart Images

Figure CN118924799A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a new application of Corymborhinus cati mycelium powder, and in particular to an application of Corymborhinus cati mycelium powder in preparing a liver protection drug. Background Art
[0002] Nonalcoholic fatty liver disease (NAFLD) is a series of chronic liver diseases characterized by excessive deposition of liver fat, i.e., fatty degeneration, in the absence of excessive drinking or other causes. NAFLD is the most common chronic liver disease in adults and the leading cause of increased liver-related morbidity and mortality. It is estimated that the global prevalence of NAFLD has increased from 25% to 38% in the past three decades, and the number of patients is also increasing at an alarming rate every year. It is expected that the overall prevalence of NAFLD worldwide will reach 55.7% by 2040. NAFLD generally occurs in adults, but in recent years, the high incidence in children has gradually increased, becoming the most common liver disease in children, with an estimated prevalence of 22.5%. The prevalence of NAFLD in China is also increasing rapidly. A systematic review and meta-analysis on the prevalence of NAFLD in China published in 2020, using 167 studies and NAFLD prevalence data of nearly 1.5 million people, found that the prevalence of NAFLD was 29.9% and was still rising. NAFLD and the various diseases it causes not only cause serious health hazards, but also impose a heavy economic burden on the entire society. Therefore, the prevention and treatment of NAFLD is urgent.
[0003] The term “nonalcoholic steatohepatitis” was first used in a landmark paper published by Ludwig et al in 1980 to describe liver histology associated with excess liver fat in the absence of heavy alcohol consumption. The term nonalcoholic fatty liver disease used by researchers stems from the histopathological similarities between these patients and those with alcoholic liver disease. Since the term nonalcoholic fatty liver disease was introduced into medical compendiums, there has been discussion about changing the name to better reflect the disease process and expand the term beyond the superficial histopathological similarities with alcoholic liver disease. In 2020, an international expert panel recommended that NAFLD be renamed metabolic associated fatty liver disease (MAFLD) and proposed diagnostic criteria: the degree of hepatocyte fat accumulation, based on histology, imaging, and blood biomarkers, and one of the following three conditions: overweight / obesity, type 2 diabetes mellitus (T2DM), and metabolic dysfunction. However, the new name has not yet been accepted by the authority. During the 2023 EASL Annual Meeting, many experts and representatives reached a "Multi-Society Delphi Consensus on the New Name of Fatty Liver Disease", suggesting that NAFLD be renamed metabolic dysfunction-associated steatotic liver disease (MASLD). Currently, the terms NAFLD, MAFLD, and MASLD exist in the academic community, but the name change of NAFLD has not been officially implemented due to controversy, so this invention still uses the previous name NAFLD.
[0004] NAFLD is a series of clinical pathological diseases, whose pathological features include non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), and cirrhosis and its complications (such as Figure 1 ).
[0005] Most NAFLD patients are asymptomatic in the early stages of non-alcoholic steatohepatitis, and advanced fibrosis, cirrhosis, liver failure, and related cardiovascular diseases are the main causes of death. Due to the lack of specific and sensitive indicators, the true prevalence of NAFLD may be higher, and liver biopsy remains the gold standard for distinguishing simple steatosis from non-alcoholic steatohepatitis and staging fibrosis. Most NAFLD patients present with non-progressive simple fatty liver, i.e., non-alcoholic fatty liver. Simple hepatic steatosis is curable and has little impact on life, so it has not received enough attention. However, the liver is the primary metabolic and detoxification organ in the human body and the main metabolic site for a variety of exogenous substances. Therefore, when fat accumulates in the liver, it is more susceptible to damage from alcohol, drugs, and various hepatotoxic substances, thereby causing a variety of diseases. Non-alcoholic steatohepatitis is a more serious form of non-alcoholic fatty liver disease, which is broadly defined as steatosis with inflammation and progressive fibrosis, which can develop into end-stage liver disease such as cirrhosis and hepatocellular carcinoma, and is the main risk of death in NAFLD. The degree of hepatic steatosis is associated with metabolic syndrome and cardiovascular risk, and severe steatosis is closely related to the progression of fibrosis in patients with NAFLD. While increasing the risk of patients with NAFLD developing cirrhosis, liver failure, and hepatocellular carcinoma, the susceptibility to non-liver-related diseases such as cardiovascular disease and cancer also increases.
[0006] At present, the mechanism of the development and progression of NAFLD is not fully understood. The "two-hit" theory first proposed by Day et al. in 1998 is the most classic theory to explain the pathogenesis of NAFLD. The "first hit" is characterized by insulin resistance and dysfunction of the synthesis and transport of triglycerides (TG) in hepatocytes. The "second hit" refers to the excessive deposition of lipids in the liver, which reacts with excessive reactive oxygen to form lipid peroxidation products, aggravating inflammation and necrosis of liver parenchymal cells. Lipid peroxidation, oxidative stress and inflammatory response are closely related to the progression of NAFLD. With the deepening of research, the "two-hit" theory is difficult to explain the complex mechanism involved in the development and progression of NAFLD. The "multiple hit" theory takes into account the multiple factors and interactions involved in NAFLD, more accurately explains the pathogenesis of NAFLD, and is widely accepted. This theory believes that insulin resistance, dietary habits, visceral obesity, inflammatory state, oxidative stress, microbiome changes and genetic susceptibility are all recognized risk factors for the development and progression of NAFLD. Whether it is the classic "two-hit" theory or the newly proposed "multiple-hit" theory, lipid metabolism disorders and oxidative stress are important factors in the occurrence and development of NAFLD.
[0007] Although some progress has been made on the pathogenesis of NAFLD, and some nonspecific antioxidant, anti-inflammatory, lipid-lowering and blood sugar-lowering drugs have been widely used in clinical practice to improve the symptoms of NAFLD, due to the complex pathogenesis of NAFLD, people's understanding of its pathogenesis is still incomplete, so there is currently no approved therapeutic drug for clinical use. Exercise training and dietary intervention remain the main treatments for patients with NAFLD and its advanced NASH. However, due to a variety of social, psychological, physical, genetic and epigenetic reasons, it is difficult for patients to maintain an improved lifestyle. Therefore, there is an urgent need to find and develop safe, effective and non-hepatotoxic natural medicines to intervene in the treatment of early NAFLD and prevent its progression to NASH. Summary of the invention
[0008] The purpose of the present invention is to provide a new use of the mycelial powder of Corydalis fuliginosa, namely, the use of the mycelial powder of Corydalis fuliginosa in preparing liver protection drugs.
[0009] In addition, the present invention claims to protect the use of the mycelial powder of Felis serrata in the preparation of a medicine for treating non-alcoholic fatty liver disease.
[0010] The above-mentioned cat's spores are selected from the strain with the preservation number of CGMCC NO.0706.
[0011] Furthermore, the preparation method of the above-mentioned mycelium powder of Corydalis cati is as follows: millet, sucrose, MgSO4, KH2PO4 and distilled water are taken to make a solid culture medium; the above-mentioned solid culture medium is encapsulated in a culture bottle, sealed with kraft paper, and sterilized at 120°C-130°C; after cooling to room temperature, the mycelium cati strain is inoculated; the inoculated culture bottle is placed in a temperature of 20°C-25°C, a relative humidity of 40%-60%, and a well-ventilated environment for fermentation and culture, and after the mycelium has grown all over the entire culture bottle, the culture is collected and dried in a drying oven to form mycelium blocks, and then the powder is obtained by a grinder, and the mycelium powder of Corydalis cati is obtained after sieving for standby use.
[0012] Furthermore, the above solid culture medium includes, by mass, 840 parts of millet, 42 parts of sucrose, 2.8 parts of MgSO4, and 5.5 parts of KH2PO4.
[0013] Dyslipidemia plays a crucial role in the pathogenesis of NAFLD. TG is the main storage and transport form of fatty acids in cells and plasma, and is mainly metabolized in the liver. TG is continuously produced and decomposed, keeping its concentration at an extremely low level. However, excessive energy intake disrupts the dynamic balance of TG production and decomposition, and fatty acid metabolism becomes abnormal, leading to liver TG accumulation and fatty degeneration. TG and TC are important indicators related to lipid metabolism, and they increase when energy metabolism in the body is abnormal. Alanine aminotransferase and aspartate aminotransferase are common indicators of liver metabolism and transport function. Under normal physiological conditions, the enzyme activity in the blood is very low. When the liver cells and mitochondrial structure are damaged, the ALT and AST in the cells flow into the blood, and their serum levels can increase significantly. Therefore, serum ALT and AST can be used as important indicators for evaluating liver damage. The World Health Organization believes that ALT is the most sensitive indicator of liver damage. In db / db mice, ALT and AST levels increased significantly compared with db / m group mice, indicating that the liver of db / db mice was severely damaged. After IFMP intervention, the levels of TG, ALT and AST in the serum of mice were significantly lower than those in the db / db group. Therefore, IFMP can significantly improve the dyslipidemia and liver damage caused by NAFLD.
[0014] Pathological morphological observation is the gold standard for diagnosing diseases. The pathological results of H&E staining and Oil Red O staining in the present invention showed that the hepatocytes of mice in the db / m group did not show fatty degeneration, hepatocyte necrosis, inflammatory cell infiltration and obvious lipid droplets. Compared with the db / m mouse group, the hepatocyte morphology of mice in the db / db group underwent obvious pathological changes: a large number of hepatocytes were fatty degenerated, a large number of round vacuoles of varying sizes were visible in the cytoplasm, accompanied by obvious ballooning and inflammatory cell infiltration, and Oil Red O staining showed large areas of red lipid droplets, and the NAS score and Oil Red O positive area were significantly increased. The number of inflammatory cell infiltration, ballooning and lipid droplets in the liver of mice in the Met, IFMP-L and IFMP-H intervention groups was significantly reduced, and the NAS score and Oil Red O positive area were significantly reduced. Therefore, IFMP can improve the degree of pathological changes in the liver tissue of db / db mice.
[0015] Oxidative stress plays an important role in the progression from simple steatosis to NASH. It is one of the most important mechanisms leading to liver damage in NAFLD and is increasingly becoming a key factor in the occurrence and development of NAFLD. The liver detoxification process is the main source of liver oxidative stress. A variety of substances such as alcohol, toxins, drugs and food undergo biotransformation in the liver, producing intermediate metabolites reactive oxygen species (ROS). An appropriate amount of ROS promotes liver detoxification and excretion. When there are too many ROS, the balance in the body will be disturbed, inducing lipid peroxidation and forming lipid peroxide MDA. The amount of MDA in the body can reflect the degree of damage caused by lipid peroxidation and indirectly reflect the degree of cell damage. Superoxide dismutase is an important component of the body's antioxidant defense system, which can catalyze the dismutation of superoxide into hydrogen peroxide and oxygen molecules and protect cells from damage. SOD can catalyze superoxide anions (O2-) as the first line of defense against ROS. Excessive ROS consumes SOD, reduces SOD activity, leads to antioxidant imbalance, oxidation of proteins, lipids, DNA / RNA, promotes oxidative stress response, and further aggravates liver damage. The results showed that compared with the db / m group of mice, the MDA content in the liver of db / db mice was significantly increased, and the SOD activity was significantly reduced, indicating that lipid peroxidation in db / db mice was severe. IFMP intervention significantly reduced the content of MDA, a lipid peroxidation product in mice, and increased the activity of superoxide dismutase, indicating that IFMP can enhance the antioxidant effect of db / db mice and reduce liver damage in non-alcoholic fatty liver disease.
[0016] In summary, the present invention mainly studies the serum indices, morphological indices, antioxidant indices and other aspects of db / db mice, and proves that IFMP can improve NAFLD by regulating the blood lipids and liver function levels of db / db mice, reducing liver lipid deposition, and resisting oxidative stress in the body. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 :The development and progression of nonalcoholic fatty liver disease.
[0018] Figure 2 : Flow chart of fermentation culture of IFMP.
[0019] Figure 3 : IFMPs prepared by culture.
[0020] Figure 4 :The effect of IFMP on body weight, food intake and water intake of db / db mice (n=5), Note: Compared with the db / m group, # P<0.05; compared with the db / db group, * P<0.05.
[0021] Figure 5 :The effect of IFMP on blood lipid and liver function of db / db mice (n=5), including (A) TG; (B) TC; (C) ALT; (D) AST. Note: Compared with db / m group, # P<0.05; compared with the db / db group, * P<0.05.
[0022] Figure 6 :Effects of IFMP on pathological changes of liver tissue in db / db mice (H&E staining (200×).
[0023] Figure 7 : NAS scores of the liver of mice in each group (n=5), Note: Compared with the db / m group, # P<0.05; compared with the db / db group, * P<0.05.
[0024] Figure 8 :Effect of IFMP on lipid accumulation in liver tissue of db / db mice Oil red O staining (200×).
[0025] Fig. 9 : Oil Red O positive area of liver tissue of mice in each group (n=5), Note: Compared with db / m group, # P<0.05; compared with the db / db group, * P<0.05. DETAILED DESCRIPTION
[0026] Isaria felina mycelium powder (IFMP) is a product of Isaria felina mycelium fungus fermentation culture. Whether it can improve NAFLD and its related mechanisms are still unclear. Therefore, this study intends to use db / db mice to conduct experiments to explore the effects of IFMP on liver damage, blood lipid metabolism and oxidative stress levels in db / db mice, and provide a theoretical basis for the development and utilization of Isaria felina mycelium powder.
[0027] 1 Materials and methods
[0028] 1.1 Experimental animals
[0029] Twenty healthy SPF male C57BL / KsJ (db / db) mice aged 7 weeks, weighing 37-43g; 5 SPF littermate control db / m mice, weighing 29-32g, were fed adaptively for one week. Both db / db mice and db / m mice were purchased from Changzhou Cavens Experimental Animal Co., Ltd. with a license number of SCXK (Su) 2021-0013 and raised in the Experimental Animal Center of Shanxi Cancer Hospital with a license number of SYXK (Jin) 2022-0003. The maintenance feed for mice and rats was purchased from Beijing Keao Xieli Feed Co., Ltd. The feeding environment: the circadian rhythm is 12h, the temperature is 22-24℃, and the humidity is 40%-60%. Ensure that the mice have sufficient food and water, change the bedding frequently, and provide a comfortable and clean environment for the mice. The animal experiment was approved by the Animal Ethics Committee of Shanxi Cancer Hospital, and the ethics registration number is: 2022040.
[0030] 1.2 Test substances
[0031] Cordyceps sinensis is a fungus isolated and cultured from the Cordyceps sinensis. It has functions similar to Cordyceps sinensis and has been shown to have a series of benefits, including immune protection, antioxidant, anti-tumor, and kidney protection. However, there is no literature report on the effect of IFMP on NAFLD.
[0032] The cat's club spore described in the present invention uses the strain with the preservation number of CGMCC NO.0706, and the preservation unit is the General Microbiology Center of China Microbiological Culture Collection Administration.
[0033] The mycelium powder of Corydalis cati is obtained by the following method: millet, sucrose, MgSO4, KH2PO4 and distilled water are used to prepare a solid culture medium; the solid culture medium is encapsulated in a culture bottle, sealed with kraft paper, and sterilized at 120-130°C; after cooling to room temperature, the mycelium cati is inoculated; the inoculated culture bottle is placed in a well-ventilated environment with a temperature of 20-25°C, a relative humidity of 40%-60% for fermentation and culture, and after the mycelium grows all over the culture bottle, the culture is collected and dried in a drying oven to form mycelium blocks, and then a grinder is used to obtain powder, and IFMP is obtained after sieving for standby use.
[0034] Preferably, the above solid culture medium comprises, by mass, 840 parts of millet, 42 parts of sucrose, 2.8 parts of MgSO4, and 5.5 parts of KH2PO4.
[0035] A relatively specific embodiment provides a fermentation method for IFMP. Figure 2 IFMP fermentation culture flow chart, see Figure 3IFMP prepared by culture. In this embodiment, the mycelial powder of Corydalis cati is obtained by the following method: 840g of millet, 42g of sucrose, 2.8g of MgSO4, 5.5g of KH2PO4 and distilled water are used to prepare a solid culture medium; the solid culture medium is packaged in a culture bottle, sealed with kraft paper, and sterilized at 125°C for 40min; after cooling to room temperature, the Corydalis cati strain is inoculated; the inoculated culture bottle is placed in a well-ventilated environment with a temperature of 22°C and a relative humidity of 50% for fermentation and culture, and after the mycelium has grown all over the culture bottle, the culture is collected and dried in a drying oven to form mycelial blocks, and then the powder is obtained by a grinder, and the IFMP is obtained by passing through a 100-mesh sieve for standby use.
[0036] 1.3 Main instruments and reagents
[0037] Main instruments
[0038]
[0039]
[0040] Main reagents
[0041]
[0042] 1.4 Experimental methods
[0043] 1.4.1 Animal grouping and intervention
[0044] Twenty db / db mice were randomly divided into four groups (5 mice in each group): model control group (db / db, gavage with distilled water), metformin positive control group (Met, gavage with 250mg / kg Met), low-dose group of mycelial powder of Felis fulgens (IFMP-L, gavage with 200mg / kg IFMP), high-dose group of mycelial powder of Felis fulgens (IFMP-H, gavage with 400mg / kg IFMP), and five 8-week-old db / m mice were used as normal control group (db / m, gavage with distilled water). The solvent of the intervention was distilled water, the gavage volume was 10ml / kg, and the gavage was continued for 8 weeks.
[0045] 1.4.2 Observation of general condition of experimental mice
[0046] Weigh and record the weight of mice once a week, and observe the activity, mental state, hair, etc. of the mice. Regularly monitor the food and water intake of each group of mice, and calculate the average daily food and water intake of each mouse.
[0047] 1.4.3 Specimen collection
[0048] (1) Blood specimen
[0049] The experiment was ended 24 h after the last intervention (all mice were fasted but not watered for 12 h), and the mice were anesthetized by intraperitoneal injection of sodium pentobarbital (60 mg / kg). The eyeballs were removed to collect blood, and the blood was allowed to stand at room temperature for 30 min and then centrifuged at 3000 r / min for 15 min. The serum was separated and stored in a -80°C refrigerator for the detection of blood biochemical indicators TG, total cholesterol (TC), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) levels.
[0050] (2) Mouse liver tissue specimens
[0051] After blood collection, the mice were killed by cervical dislocation, the liver was removed, rinsed with saline, and the liver tissue was divided into two parts: ① Part of the liver tissue was fixed in a universal tissue fixative for H&E staining and Oil Red O staining; ② The remaining liver tissue was placed in a numbered EP tube and immediately frozen in a -80°C refrigerator for the detection of liver antioxidant indicators.
[0052] 1.4.4 Serum biochemical index detection
[0053] Take the blood sample collected in 1.4.3 and analyze it on the automatic blood biochemistry analyzer.
[0054] 1.4.5 H&E staining
[0055] (1) Fixation and embedding: Fresh liver tissue specimens are fixed in a universal tissue fixative for 24 h and then placed in a dehydration box for dehydration. The paraffin is melted in the embedding machine and the liver tissue is placed in the embedding machine and cooled at -20°C.
[0056] (2) Sectioning: The thickness of the sections is 5 μm. Soak the sections in 40°C warm water and flatten them. Pick up the tissue with a glass slide and mark the number. Then bake the sections in a 60°C oven for 1 hour.
[0057] (3) Dewax and hydrate according to the steps in the following table:
[0058] Dewaxing and hydration steps
[0059]
[0060] (4) H&E staining: add hematoxylin solution to the slices, stain for 5 min, rinse with running water, differentiate with hydrochloric acid and alcohol, rinse with running water, turn blue with dilute ammonia solution, rinse with running water; add eosin solution to the slices again, stain for 5 min.
[0061] (5) Dehydrate the slices according to the steps in the following table:
[0062] Dehydration step
[0063]
[0064] (6) Sealing: After the slices are dehydrated, air dry them and seal them with neutral gum. Cover them evenly with a coverslip to avoid bubbles.
[0065] (7) Observation: Finally, the images were observed under a light microscope and semi-quantitatively analyzed using Image Pro Plus 6.0 software.
[0066] 1.4.6 NAFLD activity score (NAS)
[0067] The NAS semiquantitative scoring system was used to evaluate the degree of liver steatosis histologically. The unweighted sum of steatosis (0-3 points), lobular inflammation (0-3 points), and cellular ballooning (0-2 points) was calculated, with a score range of 0-8 (see Table 1 for details).
[0068] Table 1 NAFLD Activity Score (NAS) Histological Scoring Criteria
[0069]
[0070] 1.4.7 Oil Red O staining
[0071] (1) Tissue dehydration: Remove the fixed liver tissue from the tissue fixative, trim it, and place it in 15% and 30% sucrose solutions in a 4°C refrigerator for dehydration. The tissue can be removed from the sucrose solution only after it has completely sunk to the bottom.
[0072] (2) Frozen sections: After the tissue is dehydrated, wipe the surface moisture with filter paper, embed it with OCT embedding medium, and place it on a quick freezing table for low-temperature fixation. Adjust the tissue thickness of the freezing microtome to about 8-10μm, and place the cut tissue slices on a clean absorbent slide.
[0073] (3) Oil Red O staining: The slides were subjected to the following staining process in sequence: Oil Red O staining solution, covered and protected from light (10 min) → 60% isopropanol differentiation (3 s) → 60% isopropanol differentiation (5 s) → pure water rinse → hematoxylin staining solution (5 min) → pure water rinse → differentiation solution differentiation (5 s) → pure water rinse → bluing solution (1 s) → pure water rinse.
[0074] (4) Sealing: Seal the stained sections with glycerol gelatin and dry them for storage.
[0075] (5) Observation: The cells were observed and photographed under an optical microscope, and the positive area ratio was calculated using Image-Pro Plus 6.0 software.
[0076] 1.4.8 Detection of liver antioxidant indexes
[0077] (I) Preparation of liver tissue homogenate: Weigh 0.1g frozen liver, cut into pieces and pour into a glass homogenizer, add 0.9ml physiological saline according to the ratio of weight (g): volume (ml) = 1:9, and grind on ice. When the tissue is completely ground, pour into a centrifuge tube, centrifuge at 3000r / min for 10min, and take the supernatant, i.e. 10% homogenate supernatant, for testing.
[0078] (ii) Detection of protein concentration: After the above samples are prepared, the protein concentration is measured using a BCA protein quantification kit for calculation.
[0079] 1.4.8.1 MDA Detection
[0080] (I) Reagent preparation
[0081] Preparation of working solution: Reagent 1: Reagent 2: Reagent 3 = 0.1:3:1, prepare as needed and measure on the same day.
[0082] (II) Experimental steps
[0083] MDA experimental steps table
[0084]
[0085] Use a needle to poke a small hole in the centrifuge tube cap, close the cap and mix well. Place in a 95℃ water bath for 40 minutes, cool with running water, and then centrifuge at 4000r / min for 10 minutes to completely precipitate. Take 200μL of the supernatant in a 96-well microplate and detect the absorbance value of each well at a wavelength of 532nm.
[0086] MDA content in tissue (nmol / mgprot) =
[0087]
[0088] 1.4.8.2 SOD detection
[0089] (I) Reagent preparation
[0090] Preparation of enzyme working solution: Mix the enzyme stock solution and enzyme dilution solution in a volume ratio of 1:10 and prepare it before use.
[0091] Preparation of substrate application solution: Mix substrate stock solution and buffer solution at a volume ratio of 1:200 and prepare it before use.
[0092] (II) Experimental steps
[0093] SOD experimental steps table
[0094]
[0095] The inhibition rate of SOD was calculated according to the formula:
[0096]
[0097] Calculate the activity of SOD according to the formula:
[0098] 1.5 Statistical methods
[0099] The experimental data were analyzed using SPSS27 statistical software. Indicates. One-way ANOVA was used for comparison among multiple groups; LSD test was used for pairwise comparison when variance was equal, and Dunnett's T3 test was used for unequal variance. GraphPad 8.0.2 was used to draw graphs.
[0100] 2 Results
[0101] 2.1 General status of mice
[0102] The mice in the db / m group were in good spirits, had smooth fur, were agile, and had normal urination and defecation. The mice in the db / db group were depressed, had sparse fur, were less active, and had their bedding seriously soaked with urine. The mental state and hair condition of the mice in the Met, IFMP-L, and IFMP-H groups were slightly improved, with more agile activities and less wet bedding.
[0103] Effects of IFMP on body weight of db / db mice Figure 4 (A) The body weights of mice in the db / db and Met groups were significantly higher than those in the db / m group (P<0.05). After IFMP intervention, the body weights of db / db mice decreased, with no significant statistical difference compared with those of mice in the db / m group (P>0.05).
[0104] Effects of IFMP on food intake and water intake of db / db mice Figure 4 (BC). Compared with the db / m group, the food and water intake of the db / db group mice increased significantly (P<0.05); compared with the db / db group mice, the food and water intake of the IFMP-L group mice decreased, but the difference was not statistically significant (P>0.05). The food and water intake of the Met and IFMP-H groups mice decreased significantly (P<0.05).
[0105] 2.2 Effects of IFMP on blood lipids and liver function in db / db mice
[0106] Effects of IFMP on TG, TC, ALT, and AST in db / db mice Figure 5As shown. Compared with the db / m group, the levels of TG, TC, ALT and AST in the db / db group were significantly increased (P<0.05). After oral gavage intervention, the levels of TG, TC, ALT and AST in the Met, IFMP-L and IFMP-H groups were significantly decreased (P<0.05). This shows that Met and IFMP improved the hyperlipidemia and liver function of db / db mice.
[0107] 2.3 Effects of IFMP on the pathological structure of liver tissue in db / db mice
[0108] like Figure 6 As shown in H&E staining, the H&E staining morphology of mice in the db / m group was normal, without significant inflammatory cells and fatty degeneration. Compared with the db / m group, the liver cell morphology of mice in the db / db group showed obvious pathological changes, with cell swelling, fatty degeneration of a large number of liver cells, and a large number of round vacuoles of varying sizes in the cytoplasm accompanied by inflammatory cell infiltration. Compared with the db / db group, Met, IFMP-L and IFMP-H intervention reduced vacuolar degeneration and inflammatory cell infiltration in the liver cytoplasm of mice to varying degrees. The NAS score results of liver pathology sections are shown in Figure 1. Figure 7 As shown in the results, Met and IFMP intervention for 8 weeks significantly reduced the NAS score of mice (P<0.05). Therefore, IFMP has an improving effect on hepatic steatosis in db / db mice.
[0109] 2.4 Effect of IFMP on lipid accumulation in liver tissue of db / db mice
[0110] The results of Oil Red O staining of mouse liver sections are as follows Figure 8 As shown in the figure, in the db / m group, no red lipid droplets were observed in the hepatocytes of the mouse liver, indicating that db / m mice did not have fatty degeneration and lipid accumulation. The liver of the db / db group was almost covered with red lipid droplets, indicating that a large amount of lipid accumulation occurred in the hepatocytes. Fig. 9 As shown in the figure, compared with the db / db group, the red lipid droplets in the liver tissue of mice in the Met, IFMP-L and IFMP-H groups were significantly reduced, and the Oil Red O positive area was significantly reduced (P<0.05). Therefore, IFMP can reduce lipid accumulation in the liver of db / db mice.
[0111] 2.5 Effect of IFMP on the content of MDA, a lipid peroxidation product in the liver of db / db mice
[0112] The effect of IFMP on the content of MDA, a lipid peroxidation product in the liver of db / db mice, is shown in Table 2. Compared with the db / m group, the content of MDA in the liver of the db / db group was significantly increased (P<0.05). After oral gavage intervention, the content of MDA in the Met group, IFMP-L group, and IFMP-H group was significantly decreased (P<0.05), indicating that Met and IFMP can reduce the content of MDA in the liver of db / db mice.
[0113] Table 2 Effect of IFMP on the level of lipid peroxidation product MDA in db / db mice (x±s, n=5)
[0114]
[0115] Note: Compared with db / m group, # P<0.05; compared with the db / db group, * P<0.05.
[0116] Effect of IFMP on antioxidant capacity of liver in db / db mice
[0117] The effects of IFMP on the antioxidant capacity of liver lipids in db / db mice are shown in Table 3. Compared with the db / m group, the activity of SOD in the liver of the db / db group was significantly reduced (P<0.05). After oral gavage intervention, the SOD activity of the Met group, IFMP-L group and IFMP-H group increased significantly (P<0.05), indicating that Met and IFMP can increase the SOD activity in the liver of db / db mice.
[0118] Table 3 Effects of IFMP on antioxidant capacity of liver in db / db mice (x±s, n=5)
[0119]
[0120] Note: Compared with db / m group, # P<0.05; compared with the db / db group, * P<0.05.
Claims
1. Use of mycelium powder of Felis cati in the preparation of liver protection drugs.
2. Use of mycelium powder of Felis cati in the preparation of drugs for treating non-alcoholic fatty liver disease.
3. The use according to claim 1 or 2, characterized in that: The cat's club spore is selected from the strain with the preservation number of CGMCCNO.0706.
4. The use according to claim 3, characterized in that: Millet, sucrose, MgSO4, KH2PO4 and distilled water are used to prepare a solid culture medium; the solid culture medium is encapsulated in a culture bottle, sealed with kraft paper, and sterilized at 120°C-130°C; after cooling to room temperature, the fungus species are inoculated; the inoculated culture bottle is placed in a well-ventilated environment with a temperature of 20°C-25°C and a relative humidity of 40%-60% for fermentation and culture, and after the mycelium has grown all over the culture bottle, the culture is collected and dried in a drying oven to form mycelium blocks, and then a grinder is used to obtain powder, and the mycelium powder of the fungus is sieved for standby use.
5. The use according to claim 4, characterized in that: The above solid culture medium includes, by mass, 840 parts of millet, 42 parts of sucrose, 2.8 parts of MgSO4, and 5.5 parts of KH2PO4.
Citation Information
Patent Citations
Application of Isaria felina crude polysaccharide to preparation of anti-tumor drug
CN102813669A
Application of isaria feline mycelium
CN110664849A
Cited By
Application of isaria feline mycelium in preparation of product for improving glucose and lipid metabolism disorder induced by high fat diet
CN121102294A
